Alicia Morgans, MD

Alicia Morgans, MD, MPH is an Associate Professor of Medicine at Harvard Medical School and the Medical Director of the Adult Survivorship Program at Dana-Farber Cancer Institute in Boston, MA. She completed her MD and internal medicine residency at the University of Pennsylvania Perelman School of Medicine, and her fellowship at Dana Farber Cancer Institute/MGH Cancer Center. While a faculty member at Vanderbilt University, she earned a Master of Public Health degree. She joined the team at Dana-Farber to elevate survivorship and therapeutic research for genitourinary cancer survivors and others. She is a clinician and physician investigator specializing is investigating complications of systemic therapy for prostate cancer survivors. Her work has included the study of skeletal, cardiovascular, diabetic, and cognitive complications of prostate cancer survivorship, as well as treatment decision making in the metastatic prostate cancer population. In addition, she has been awarded several federal and foundation grants to investigate the cognitive effects of hormonal treatments in advanced prostate cancer, and treatment decisions in men with metastatic prostate cancer. She also has nationally recognized expertise in patient reported outcome and quality of life studies in men with advanced prostate cancer, and as well as incorporating patient preferences and beliefs into clinical decision making. Dr. Morgans serves as the Principal Investigator and Collaborating Investigator for multiple national therapeutic prostate cancer trials.
Financial relationships
-
Attribution:SelfType of financial relationship:Consultant or Advisor (General Urology)Ineligible company:NovartisMitigation strategy:Peer reviewDate reviewed:09/20/2022
-
Attribution:SelfType of financial relationship:Consultant or Advisor (Oncology)Ineligible company:Advanced Accelerator ApplicationsMitigation strategy:Peer reviewDate reviewed:09/20/2022
-
Attribution:SelfType of financial relationship:Consultant or Advisor (General Urology)Ineligible company:MyovantMitigation strategy:Peer reviewDate reviewed:09/20/2022
-
Attribution:SelfType of financial relationship:Consultant or Advisor (General Urology)Ineligible company:PfizerMitigation strategy:Peer reviewDate reviewed:09/20/2022
-
Attribution:SelfType of financial relationship:Consultant or Advisor (General Urology)Ineligible company:BMSMitigation strategy:Peer reviewDate reviewed:09/20/2022
-
Attribution:SelfType of financial relationship:Consultant or Advisor (General Urology)Ineligible company:MerckMitigation strategy:Peer reviewDate reviewed:09/20/2022
-
Attribution:SelfType of financial relationship:Consultant or Advisor (General Urology)Ineligible company:DendreonMitigation strategy:Peer reviewDate reviewed:09/20/2022
-
Attribution:SelfType of financial relationship:Consultant or Advisor (Oncology)Ineligible company:ClovisMitigation strategy:Peer reviewDate reviewed:09/20/2022
-
Attribution:SelfType of financial relationship:Consultant or Advisor (General Urology)Ineligible company:JanssenMitigation strategy:Peer reviewDate reviewed:09/20/2022
-
Attribution:SelfType of financial relationship:Consultant or Advisor (Oncology)Ineligible company:TelixMitigation strategy:Peer reviewDate reviewed:09/20/2022